SCHEMBL2294893

SCHEMBL2294893

COC(=O)[C@@H](NC(=S)c1cc(-c2ccc(Nc3nc4ccc(F)cc4s3)cc2)no1)C(C)C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSGALNACT1 Q8TDX6 8/20 0.55
DGAT1 O75907 2/20 0.55
MAPT P10636 6/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
HPGD P15428 3/20 0.44
KDM4E B2RXH2 3/20 0.44
LMNA P02545 3/20 0.44
GAA P10253 2/20 0.44
MEN1 O00255 2/20 0.44
HTT P42858 2/20 0.44
KMT2A Q03164 2/20 0.44
TNF P01375 1/20 0.44
NR2F2 P24468 1/20 0.44
MCL1 Q07820 1/20 0.44
KLF5 Q13887 1/20 0.44
NOD1 Q9Y239 1/20 0.44
RAB9A P51151 4/20 0.42
NPC1 O15118 3/20 0.42
ALDH1A1 P00352 2/20 0.41
ALPL P05186 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2297122 1.00 CSGALNACT1 (0.55) CSGALNACT1DGAT1MAPTSMN1; SMN2HPGD
SCHEMBL2294901 1.00 CSGALNACT1 (0.55) CSGALNACT1DGAT1MAPTSMN1; SMN2HPGD
SCHEMBL2294366 0.92 CSGALNACT1 (0.61) CSGALNACT1DGAT1MAPTSMN1; SMN2HPGD
SCHEMBL2294357 0.92 CSGALNACT1 (0.61) CSGALNACT1DGAT1MAPTSMN1; SMN2HPGD
SCHEMBL2296732 0.92 CSGALNACT1 (0.61) CSGALNACT1DGAT1MAPTSMN1; SMN2HPGD
SCHEMBL2297843 0.92 CSGALNACT1 (0.66) CSGALNACT1DGAT1MAPTSMN1; SMN2RAB9A
SCHEMBL2297826 0.92 CSGALNACT1 (0.66) CSGALNACT1DGAT1MAPTSMN1; SMN2RAB9A
SCHEMBL2299494 0.92 CSGALNACT1 (0.66) CSGALNACT1DGAT1MAPTSMN1; SMN2RAB9A
SCHEMBL2297850 0.92 CSGALNACT1 (0.47) CSGALNACT1DGAT1MAPTSMN1; SMN2HPGD
SCHEMBL2297854 0.92 CSGALNACT1 (0.47) CSGALNACT1DGAT1MAPTSMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US claimed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US claimed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO claimed
US-8835428-B2 Diacylglycerol acyltransferase inhibitors Piramal Enterprises Limited (IN) 2014-09-16 US disclosed
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED. 2011-08-11 US disclosed
WO-2010023609-A1 OXAZOLE, OXADIAZOLE AND THIAZOLE DERIVATIVES AS DIACYLGLYCEROL ACYLTRANFERASE INHIBITORS PIRAMAL LIFE SCIENCES LIMITED (IN) 2010-03-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110196002-A1 DIACYLGLYCEROL ACYLTRANSFERASE INHIBITORS DGAT1, DGAT2, DLAT CSGALNACT1 455/4885DGAT1 1/4885MAPT 1278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.